DrugCite
Search

INTEGRILIN

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Integrilin Adverse Events Reported to the FDA Over Time

How are Integrilin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Integrilin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Integrilin is flagged as the suspect drug causing the adverse event.

Most Common Integrilin Adverse Events Reported to the FDA

What are the most common Integrilin adverse events reported to the FDA?

Thrombocytopenia
201 (5.48%)
Hypotension
75 (2.05%)
Platelet Count Decreased
71 (1.94%)
Haemorrhage Intracranial
70 (1.91%)
Haemorrhage
64 (1.75%)
Post Procedural Complication
58 (1.58%)
Retroperitoneal Haemorrhage
56 (1.53%)
Thrombosis
41 (1.12%)
Gastrointestinal Haemorrhage
38 (1.04%)
Myocardial Infarction
37 (1.01%)
Cardiogenic Shock
36 (.98%)
Show More Show More
Post Procedural Haemorrhage
35 (.95%)
Cardio-respiratory Arrest
34 (.93%)
Nausea
34 (.93%)
Cardiac Arrest
33 (.9%)
Petechiae
33 (.9%)
Haematoma
31 (.85%)
Haemoptysis
31 (.85%)
Bradycardia
29 (.79%)
Chest Pain
29 (.79%)
Pulmonary Oedema
29 (.79%)
Vomiting
29 (.79%)
Cerebral Haemorrhage
27 (.74%)
Haematemesis
27 (.74%)
Haemoglobin Decreased
27 (.74%)
Procedural Complication
27 (.74%)
Pulmonary Haemorrhage
27 (.74%)
Death
26 (.71%)
Dyspnoea
25 (.68%)
Pulmonary Alveolar Haemorrhage
25 (.68%)
Coronary Artery Thrombosis
24 (.65%)
Drug Ineffective
24 (.65%)
Blood Creatine Phosphokinase Mb Inc...
23 (.63%)
Cardiac Tamponade
21 (.57%)
Cerebrovascular Accident
21 (.57%)
Pneumonia
21 (.57%)
Ecchymosis
19 (.52%)
Pleural Effusion
19 (.52%)
Tachycardia
19 (.52%)
Agitation
18 (.49%)
Blood Pressure Decreased
18 (.49%)
Vascular Pseudoaneurysm
18 (.49%)
Acute Myocardial Infarction
17 (.46%)
Catheter Site Haemorrhage
17 (.46%)
Confusional State
17 (.46%)
Epistaxis
17 (.46%)
Headache
17 (.46%)
Hyperglycaemia
17 (.46%)
Injection Site Haemorrhage
17 (.46%)
Pulmonary Embolism
17 (.46%)
Renal Failure
17 (.46%)
Coronary Artery Occlusion
16 (.44%)
Haematocrit Decreased
16 (.44%)
Haemothorax
16 (.44%)
Overdose
16 (.44%)
Post Procedural Haematoma
16 (.44%)
Convulsion
15 (.41%)
Hypersensitivity
15 (.41%)
Multi-organ Failure
15 (.41%)
Subarachnoid Haemorrhage
15 (.41%)
Wound Secretion
15 (.41%)
Anaemia
14 (.38%)
Disseminated Intravascular Coagulat...
14 (.38%)
Haematuria
14 (.38%)
Medication Error
14 (.38%)
Unresponsive To Stimuli
14 (.38%)
Atrial Fibrillation
13 (.35%)
Gingival Bleeding
13 (.35%)
Pyrexia
13 (.35%)
Tachypnoea
13 (.35%)
Ventricular Tachycardia
13 (.35%)
Anaphylactic Reaction
12 (.33%)
Diarrhoea
12 (.33%)
Chills
11 (.3%)
International Normalised Ratio Incr...
11 (.3%)
Meningitis Viral
11 (.3%)
Pericardial Haemorrhage
11 (.3%)
Respiratory Failure
11 (.3%)
Tremor
11 (.3%)
Asthenia
10 (.27%)
Back Pain
10 (.27%)
Brain Herniation
10 (.27%)
Cardiac Procedure Complication
10 (.27%)
Catheter Site Discharge
10 (.27%)
Coronary Artery Stenosis
10 (.27%)
Drug Specific Antibody Present
10 (.27%)
Electrocardiogram St Segment Elevat...
10 (.27%)
Mouth Haemorrhage
10 (.27%)
Renal Failure Acute
10 (.27%)
Respiratory Arrest
10 (.27%)
Ventricular Fibrillation
10 (.27%)
Angina Pectoris
9 (.25%)
Blood Creatine Phosphokinase Increa...
9 (.25%)
Cerebral Ischaemia
9 (.25%)
Coagulation Time Abnormal
9 (.25%)
Coagulation Time Prolonged
9 (.25%)
Deep Vein Thrombosis
9 (.25%)
Haemodynamic Instability
9 (.25%)
Metabolic Acidosis
9 (.25%)
Pneumothorax
9 (.25%)
Cerebral Infarction
8 (.22%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Integrilin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Integrilin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Integrilin

What are the most common Integrilin adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Integrilin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Integrilin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Integrilin According to Those Reporting Adverse Events

Why are people taking Integrilin, according to those reporting adverse events to the FDA?

Drug Use For Unknown Indication
151
Coronary Angioplasty
112
Antiplatelet Therapy
86
Acute Coronary Syndrome
81
Percutaneous Coronary Intervention
63
Product Used For Unknown Indication
62
Show More Show More
Myocardial Infarction
58
Acute Myocardial Infarction
54
Stent Placement
34
Catheterisation Cardiac
29
Coronary Artery Disease
22
Angioplasty
20
Therapeutic Procedure
18
Coronary Arterial Stent Insertion
18
Anticoagulant Therapy
14
Prophylaxis
14
Angina Unstable
12
Chest Pain
8
Cardiac Operation
7
Arteriogram Coronary
6
Peripheral Artery Angioplasty
5
Thrombosis
5
Electrocardiogram St Segment Elevat...
5
Thrombosis Prophylaxis
4
Stent Removal
4
Arterial Occlusive Disease
4
Coronary Artery Surgery
3
Arterial Repair
3
Cardiac Ventriculogram Left
3
Angina Pectoris
3
Ill-defined Disorder
3
Cardiac Disorder
3
Coagulopathy
2
Arterial Catheterisation
2
Carotid Artery Stent Insertion
2
Postoperative Care
2
Angiogram
2
Coronary Artery Bypass
2
Cardiac Arrest
2
Platelet Aggregation Inhibition
2
Off Label Use
2
Biopsy Kidney
1
Vascular Occlusion
1
Thrombosis In Device
1
Arteriosclerosis Coronary Artery
1
Peripheral Vascular Disorder
1
Chest Discomfort
1
Cerebrovascular Accident
1
Muscular Weakness
1
Cardiogenic Shock
1
Thrombolysis
1

Drug Labels

LabelLabelerEffective
IntegrilinMerck Sharp & Dohme Corp.25-MAR-13

Integrilin Case Reports

What Integrilin safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Integrilin. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Integrilin.